Ciola Bennett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ciola Bennett has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Catherine R. Marinac
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
7 shared publications - Elizabeth K. O’ Donnell
Dana-Farber Cancer Institute 3 Boston, MA
7 shared publications - Ella Matthews
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
7 shared publications - Giovanni Parmigiani
Dana-Farber Cancer Institute
7 shared publications - Harita Dharaneeswaran
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
7 shared publications - Irene M. Ghobrial
Harvard Medical School, Boston, Massachusetts
7 shared publications
Latest Publications
- Open Access
- 9 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Supplementary Table 1 shows the primary and secondary CSOs from the MCED test and the diagnostic evaluations performed.
- 9 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Supplementary Table 1 shows the primary and secondary CSOs from the MCED test and the diagnostic evaluations performed.
- Open Access
- 9 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Supplementary Appendix shows the referral and diagnostic timelines for the 14 patients presenting with a cancer signal-detected MCED test.
- 9 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Supplementary Appendix shows the referral and diagnostic timelines for the 14 patients presenting with a cancer signal-detected MCED test.
- Open Access
- 9 March 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Characteristics of adults with cancer signal detected by Grail Galleri Test at DFCI MCEDa Program (n = 14).
- 9 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Characteristics of adults with cancer signal detected by Grail Galleri Test at DFCI MCEDa Program (n = 14).
- Open Access
- 9 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Supplementary Table 2 shows our general approach for performing a clinical evaluation of a patient with a cancer signal-detected test result.
- 9 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Supplementary Table 2 shows our general approach for performing a clinical evaluation of a patient with a cancer signal-detected test result.
- Open Access
- 9 March 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Source of baseline MCED tests and referral patterns.
- 9 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Source of baseline MCED tests and referral patterns.
- Open Access
- 9 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Multi-cancer early detection (MCED) tests represent a significant technological advancement, allowing for the detection of multiple cancers through a single screening test. In December 2023, Dana-Farber Cancer Institute (DFCI) initiated an MCED clinical and research program to serve patients receiving positive MCED test results and further study MCED tests in clinical practice. Prospective case series reporting on patients with a signal detected by the Grail Galleri MCED test who presented for diagnostic evaluation at DFCI between December 2023 and January 2025. Primary outcomes were confirmation of cancer diagnosis, time to diagnostic resolution, and accuracy of the cancer signal origin (CSO) suggested. Of the 14 patients with a positive MCED test, 78.6% had a confirmed cancer diagnosis, whereas 21.4% were false positives. The median age was 62.5 years, with 64.3% male and 85.7% White, non-Hispanic. The median time from MCED test result to presentation at the DFCI MCED clinic was 28 days. The median time from MCED clinic presentation to diagnostic resolution was 20 days. Among confirmed cases, 54.5% were solid tumors and 45.5% were hematologic malignancies. More than 90% of detected malignancies lack current screening guidelines. Six cancers were diagnosed at stage I/II, and five at III/IV. Most patients with a cancer signal detected on a MCED test were true positives with a cancer consistent with the CSO reported. Patients had their MCED test results quickly adjudicated when presenting to a dedicated clinical program supporting a role for cancer diagnostic expertise in evaluating MCED tests.Significance:MCED tests are a new and evolving technology that may help detect cancer early on. Here, we report the experience of a dedicated cancer clinic in evaluating patients with a positive cancer signal from an MCED test.
- 9 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Multi-cancer early detection (MCED) tests represent a significant technological advancement, allowing for the detection of multiple cancers through a single screening test. In December 2023, Dana-Farber Cancer Institute (DFCI) initiated an MCED clinical and research program to serve patients receiving positive MCED test results and further study MCED tests in clinical practice. Prospective case series reporting on patients with a signal detected by the Grail Galleri MCED test who presented for diagnostic evaluation at DFCI between December 2023 and January 2025. Primary outcomes were confirmation of cancer diagnosis, time to diagnostic resolution, and accuracy of the cancer signal origin (CSO) suggested. Of the 14 patients with a positive MCED test, 78.6% had a confirmed cancer diagnosis, whereas 21.4% were false positives. The median age was 62.5 years, with 64.3% male and 85.7% White, non-Hispanic. The median time from MCED test result to presentation at the DFCI MCED clinic was 28 days. The median time from MCED clinic presentation to diagnostic resolution was 20 days. Among confirmed cases, 54.5% were solid tumors and 45.5% were hematologic malignancies. More than 90% of detected malignancies lack current screening guidelines. Six cancers were diagnosed at stage I/II, and five at III/IV. Most patients with a cancer signal detected on a MCED test were true positives with a cancer consistent with the CSO reported. Patients had their MCED test results quickly adjudicated when presenting to a dedicated clinical program supporting a role for cancer diagnostic expertise in evaluating MCED tests.Significance:MCED tests are a new and evolving technology that may help detect cancer early on. Here, we report the experience of a dedicated cancer clinic in evaluating patients with a positive cancer signal from an MCED test.
- Open Access
- 1 March 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (3) , 511-515
Diagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Multi-cancer early detection (MCED) tests represent a significant technological advancement, allowing for the detection of multiple cancers through a single screening test. In December 2023, Dana-Farber Cancer Institute (DFCI) initiated an MCED clinical and research program to serve patients receiving positive MCED test results and further study MCED tests in clinical practice. Prospective case series reporting on patients with a signal detected by the Grail Galleri MCED test who presented for diagnostic evaluation at DFCI between December 2023 and January 2025. Primary outcomes were confirmation of cancer diagnosis, time to diagnostic resolution, and accuracy of the cancer signal origin (CSO) suggested. Of the 14 patients with a positive MCED test, 78.6% had a confirmed cancer diagnosis, whereas 21.4% were false positives. The median age was 62.5 years, with 64.3% male and 85.7% White, non-Hispanic. The median time from MCED test result to presentation at the DFCI MCED clinic was 28 days. The median time from MCED clinic presentation to diagnostic resolution was 20 days. Among confirmed cases, 54.5% were solid tumors and 45.5% were hematologic malignancies. More than 90% of detected malignancies lack current screening guidelines. Six cancers were diagnosed at stage I/II, and five at III/IV. Most patients with a cancer signal detected on a MCED test were true positives with a cancer consistent with the CSO reported. Patients had their MCED test results quickly adjudicated when presenting to a dedicated clinical program supporting a role for cancer diagnostic expertise in evaluating MCED tests. Significance: MCED tests are a new and evolving technology that may help detect cancer early on. Here, we report the experience of a dedicated cancer clinic in evaluating patients with a positive cancer signal from an MCED test.
- 1 March 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (3) , 511-515
Open AccessDiagnostic Outcomes among Patients with Positive Multi-Cancer Early Detection Test Results
Multi-cancer early detection (MCED) tests represent a significant technological advancement, allowing for the detection of multiple cancers through a single screening test. In December 2023, Dana-Farber Cancer Institute (DFCI) initiated an MCED clinical and research program to serve patients receiving positive MCED test results and further study MCED tests in clinical practice. Prospective case series reporting on patients with a signal detected by the Grail Galleri MCED test who presented for diagnostic evaluation at DFCI between December 2023 and January 2025. Primary outcomes were confirmation of cancer diagnosis, time to diagnostic resolution, and accuracy of the cancer signal origin (CSO) suggested. Of the 14 patients with a positive MCED test, 78.6% had a confirmed cancer diagnosis, whereas 21.4% were false positives. The median age was 62.5 years, with 64.3% male and 85.7% White, non-Hispanic. The median time from MCED test result to presentation at the DFCI MCED clinic was 28 days. The median time from MCED clinic presentation to diagnostic resolution was 20 days. Among confirmed cases, 54.5% were solid tumors and 45.5% were hematologic malignancies. More than 90% of detected malignancies lack current screening guidelines. Six cancers were diagnosed at stage I/II, and five at III/IV. Most patients with a cancer signal detected on a MCED test were true positives with a cancer consistent with the CSO reported. Patients had their MCED test results quickly adjudicated when presenting to a dedicated clinical program supporting a role for cancer diagnostic expertise in evaluating MCED tests. Significance: MCED tests are a new and evolving technology that may help detect cancer early on. Here, we report the experience of a dedicated cancer clinic in evaluating patients with a positive cancer signal from an MCED test.